NCT06731868View on ClinicalTrials.gov

Safety and Efficacy of LPM3770164 Sustained-release Tablets in Patients With Tardive Dyskinesia

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

January 14, 2025

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2025

Conditions
Tardive Dyskinesia (TD)
Interventions
DRUG

LPM3770164 sustained release tablet 5 mg

LPM3770164 sustained release tablet once daily oral dosage at 5 mg for 6 weeks

DRUG

LPM3770164 sustained release tablet 10 mg

LPM3770164 sustained release tablet once daily oral dosage at 10 mg for 6 weeks.

DRUG

LPM3770164 sustained release tablet 20 mg

LPM3770164 sustained release tablet once daily oral dosage at 20 mg for 6 weeks.

DRUG

LPM3770164 sustained release tablet simulant

LPM3770164 sustained release tablet simulant once daily oral for 6 weeks.

Trial Locations (1)

Unknown

RECRUITING

Shanghai Mental Health Center, Shanghai

All Listed Sponsors
lead

Luye Pharma Group Ltd.

INDUSTRY